


# Corporate Profile / Main Group Companies

## Corporate Profile

(As of April 1, 2021)

Company name DAIICHI SANKYO CO., LTD.  
 Established September 28, 2005  
 Business Research and development, manufacturing, import, sales, and marketing of pharmaceutical products  
 Share capital ¥50,000 million  
 Headquarters 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan  
 Branches Sapporo, Tohoku, Tokyo, Chiba, Saitama, Yokohama, Kanetsu, Tokai, Kyoto, Osaka, Kobe, Chugoku, Shikoku, and Kyushu




- Daiichi Sankyo Europe GmbH
- Daiichi Sankyo Deutschland GmbH
- Daiichi Sankyo France SAS
- Daiichi Sankyo Italia S.p.A.
- Daiichi Sankyo España, S.A.U.
- Daiichi Sankyo UK Ltd.
- Daiichi Sankyo (Schweiz) AG
- Daiichi Sankyo Portugal, Unipessoal Lda.
- Daiichi Sankyo Austria GmbH
- Daiichi Sankyo Belgium N.V.-S.A.
- Daiichi Sankyo Nederland B.V.
- Daiichi Sankyo Ilac Ticaret Ltd. Şti.
- Daiichi Sankyo Ireland Ltd.
- Daiichi Sankyo Altkirch Sarl

Revenue (Billions of yen)			
	FY2019 Results	FY2020 Results	YoY
Daiichi Sankyo Europe	95.5	111.7	+16.1
ENHERTU	-	0.0	0.0
LIXIANA	61.7	76.7	+15.0
Olmesartan	24.6	21.5	-3.1
Efient	2.5	1.6	-0.9

- Daiichi Sankyo Espha Co., Ltd.
- Daiichi Sankyo Healthcare Co., Ltd.
- Daiichi Sankyo Propharma Co., Ltd.
- Daiichi Sankyo Chemical Pharma Co., Ltd.
- Daiichi Sankyo Biotech Co., Ltd.
- Daiichi Sankyo RD Novare Co., Ltd.
- Daiichi Sankyo Business Associe Co., Ltd.
- Daiichi Sankyo Happiness Co., Ltd.

Revenue (Billions of yen)			
	FY2019 Results	FY2020 Results	YoY
Domestic Prescription Drug and Vaccine Business	533.5	489.1	-44.4
NEXIUM	79.8	77.8	-1.9
LIXIANA	83.0	77.4	-5.6
PRALIA	30.9	34.6	+3.7
TENELIA	24.7	24.2	-0.5
Loxonin	28.3	24.2	-4.1
Tarige	8.0	20.6	+12.6
RANMARK	17.9	19.3	+1.4
Memary	50.5	18.4	-32.1
CANALIA	12.8	15.4	+2.6
VIMPAT	11.2	14.5	+3.4
Efient	14.0	14.1	+0.1
Rezaltas	14.6	13.1	-1.5
Olmotec	11.7	9.2	-2.4
ENHERTU	-	4.4	+4.4
Inavir	19.3	3.6	-15.6
Daiichi Sankyo Healthcare (OTC Related)	68.5	67.2	-1.3

Sales Manufacturing Research and development



- Daiichi Sankyo, Inc.
- American Regent, Inc.
- Plexxikon Inc.

Revenue (Billions of yen)			
	FY2019 Results	FY2020 Results	YoY
Daiichi Sankyo, Inc.	32.1	47.4	+15.3
Enherthu	3.2	25.7	+22.5
Olmesartan	9.8	8.6	-1.3
Welchol	9.1	5.0	-4.1
SAVAYSA	2.6	3.0	+0.4
Efient	0.5	0.3	-0.1
American Regent, Inc.	130.8	121.7	-9.1
Injectafer	51.8	44.1	-7.7
Venofer	31.0	28.8	-2.2

- Daiichi Sankyo (China) Holdings Co., Ltd.
- Daiichi Sankyo Taiwan Ltd.
- Daiichi Sankyo Korea Co., Ltd.
- Daiichi Sankyo (Thailand) Ltd.
- Daiichi Sankyo Vietnam Co., Ltd.
- Daiichi Sankyo Hong Kong Ltd.
- Daiichi Sankyo Brasil Farmaceutica LTDA.

Revenue (Billions of yen)			
	FY2019 Results	FY2020 Results	YoY
Asia, South & Central America (ASCA)	98.3	99.7	+1.3
Daiichi Sankyo China	46.0	45.6	-0.4
Daiichi Sankyo Korea	17.2	19.6	+2.4
Daiichi Sankyo Brasil	11.5	10.5	-1.0
Daiichi Sankyo Taiwan	7.6	8.3	+0.7
Daiichi Sankyo Thailand	3.3	2.3	-1.1

## Number of Bases

(As of March 31, 2021)

Group companies: **50** | Number of countries/regions with bases: **24** | R&D bases: **17** bases in **10** countries/regions | Production bases: **13** bases in **6** countries/regions